Pataday and Psoriasis - a phase IV clinical study of FDA data

Summary:

Psoriasis is reported as a side effect among people who take Pataday (olopatadine hydrochloride), especially for people who are female, 60+ old, also take Humira, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Psoriasis when taking Pataday. It is created by eHealthMe based on reports of 8,221 people who have side effects when taking Pataday from the FDA, and is updated regularly.

What is Pataday?

Pataday has active ingredients of olopatadine hydrochloride. It is often used in allergies. eHealthMe is studying from 8,288 Pataday users. Check the latest studies of Pataday.

What is Psoriasis?

Psoriasis (immune-mediated disease that affects the skin) is found to be associated with 1,480 drugs and 1,694 conditions by eHealthMe. Check the latest studies of Psoriasis.

On Jul, 09, 2026

8,221 people reported to have side effects when taking Pataday.
Among them, 19 people (0.23%) have Psoriasis.

Among these 19 people:

What is the gender of people who have Psoriasis when taking Pataday? *

female: 68.42 %
male: 31.58 %

What is the age of people who have Psoriasis when taking Pataday? *

What are other drugs people take besides Pataday? *

What are other side effects people have besides Psoriasis? *

Joint Pain: 9 people, 47.37%
Diarrhea: 7 people, 36.84%
Fatigue (feeling of tiredness): 7 people, 36.84%
Gait Disturbance: 7 people, 36.84%
Rashes (redness): 6 people, 31.58%
Dyspnea (difficult or laboured breathing): 6 people, 31.58%
Fall: 6 people, 31.58%
Weakness: 6 people, 31.58%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 31.58%
Nausea And Vomiting: 6 people, 31.58%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 5 people, 26.32%
Hypersensitivity: 4 people, 21.05%
Dry Eyes (lack of adequate tears): 3 people, 15.79%
Inflammation: 2 people, 10.53%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 10.53%
Pain: 2 people, 10.53%
High Blood Pressure: 2 people, 10.53%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 10.53%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 2 people, 10.53%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 10.53%

* Approximation only. Some reports may have incomplete information.

Do you take Pataday and have Psoriasis?

- Check whether Psoriasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pataday:

Pataday (8,288 reports)

Psoriasis treatments and more:

Psoriasis (508,163 reports)

Browse all side effects of Pataday:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Psoriasis:

Psoriasis (1,480 drugs)

Browse all the conditions that are associated with Psoriasis:

Psoriasis (1,694 conditions)

Related publications that referenced our studies

Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Mohagheghi MA, Omranipur R, Ensani F, Ghannadan A, Shahriaran S, Samiee F, Sedighi Z, "A Case of Advanced Unicentric Retroperitoneal Castleman's Disease, Associated With Psoriasis", Acta Medica Iranica, 2017 May .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on olopatadine hydrochloride (the active ingredients of Pataday) and Pataday (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.